Mylan Receives Tentative FDA Approval for the Generic Version of the Antidepressant Effexor XR(R)

Tuesday, November 18, 2008 General News J E 4
PITTSBURGH, Nov. 17 Mylan Inc. (NYSE: MYL) todayannounced that its subsidiary, Mylan Pharmaceuticals Inc., received tentativeapproval from the U.S. Food and Drug Administration (FDA) for its AbbreviatedNew Drug Application (ANDA) for Venlafaxine Hydrochloride (HCl)Extended-release (ER) Capsules, 37.5 mg (base), 75 mg (base) and 150 mg(base).

Venlafaxine HCl ER Capsules, indicated for the treatment of majordepressive disorder and generalized anxiety disorder, are the generic versionof Wyeth Pharmaceutical Inc.'s Effexor XR(R) Capsules. This product had annualU.S. sales of approximately $3 billion for the 12 months ending Sept. 30,2008, for the noted strengths, according to IMS Health.

Currently, Mylan has 112 ANDAs pending FDA approval, 23 of which arepotential first-to-file opportunities.

Mylan Inc., which provides products to customers in more than 140countries and territories, ranks among the leading diversified generic andspecialty pharmaceutical companies in the world. The company maintains one ofthe industry's broadest -- and highest quality -- product portfolios,supported by a robust product pipeline; owns a controlling interest in theworld's third largest active pharmaceutical ingredient manufacturer; andoperates a specialty business focused on respiratory and allergy therapies.For more information, please visit

SOURCE Mylan Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Welch's Announces Partnership With The Doctors
Prominent Dermatologist Practice in Montgomery Cou...